<DOC>
	<DOCNO>NCT00975000</DOCNO>
	<brief_summary>Hyperparathyroidism ( HPT ) common people kidney transplant . Patients HPT often high parathyroid hormone ( PTH ) level may large parathyroid gland neck . Patients HPT develop bone disease ( osteodystrophy ) . This bone disease cause bone pain , fracture , poor formation red blood cell . Other problem HPT may include increase blood level calcium ( hypercalcemia ) low blood level phosphorus ( hypophosphatemia ) . The high calcium level may cause calcium deposit body tissue . Calcium deposit cause arthritis ( joint pain swell ) , muscle inflammation , itching , gangrene ( death soft tissue ) , heart lung problem kidney transplant dysfunction ( worsen kidney transplant function ) . The purpose study evaluate effect cinacalcet ( Sensipar/Mimpara ) high calcium level blood patient HPT kidney transplant .</brief_summary>
	<brief_title>Treatment Autonomous Hyperparathyroidism Post Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hypercalcemia</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Received kidney transplant ≥ 9 week time Screening ≤ 24 month first dose May first kidney transplant repeat kidney transplant . Subjects functional , stable kidney transplant , define MDRD estimate glomerular filtration rate ( eGFR ) ≥ 30 mL/min/1.73 m² ( chromic kidney disease stage 3 good ) Screening . Men woman ≥ 18 year start Screening ( ie , time informed consent ) . Corrected total serum calcium &gt; 10.5 mg/dL ( 2.63 mmol/L ) , define mean 2 value Screening period . iPTH &gt; 100 pg/mL ( 10.6 pmol/L ) , Screening period ( obtain either Screen 1 Screen 2 ) . Received cinacalcet therapy posttransplant 14 day cumulatively posttransplant . If cinacalcet therapy receive total 14 day less posttransplant , must 4week washout subject eligible screening ( Note : This exclude pretransplant use cinacalcet ) . Anticipated parathyroidectomy within 6 to12 month Randomization . Ongoing therapy bisphosphonates use within 6 month prior Screening . Ongoing use 1,25dihydroxyvitamin D3 ( include active vitamin D metabolites analogue ) use within 30 day prior Screening . Ongoing use calcium supplement use within 30 day prior Screening . Ongoing use phosphate binder ( calcium noncalcium contain ) use within 30 day prior Screening . Ongoing use thiazide diuretic . Subjects history seizures seizure within 3 month prior Randomization , require adjustment seizure medication . Acute Kidney Injury ( AKI ) renal biopsy within 6 week prior Screening , unless institutional protocoldriven biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Intervention</keyword>
	<keyword>Cinacalcet</keyword>
	<keyword>Sensipar</keyword>
	<keyword>Mimpara</keyword>
	<keyword>hyperparathyroidism</keyword>
	<keyword>calcium</keyword>
	<keyword>osteodystrophy</keyword>
	<keyword>hypercalcemia</keyword>
	<keyword>renal</keyword>
	<keyword>transplant</keyword>
	<keyword>acute rejection</keyword>
	<keyword>kidney transplant failure</keyword>
	<keyword>hypophosphatemia</keyword>
</DOC>